A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
We conducted a phase II study to determine the response rate and toxicity of weekly docetaxel and a flat dose capecitabine (days 5–18 of the 28-day cycle) in patients with incurable locally recurrent or metastatic head and neck cancers. The responses at 4 months were analyzed among 36 patients. Although the response rate was modest (11%), the 6.5 months estimated median survival was comparable to the standard platinum and 5-FU combination regimens. Major grade 3 and 4 toxicities included lymphopenia, infection, and fatigue. In view of low efficacy, this particular regimen does not appear to warrant further study.
Zhang
Jingsong
J
Department of Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, USA.
Lee
Julia
J
Urba
Susan
S
Foster
Jared
J
Worden
Francis
F
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D016022:Case-Control Studies; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D005472:Fluorouracil